Furosemide: Potent Loop Diuretic for Effective Fluid Management
Furosemide
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.77 | $46.00 (0%) | 🛒 Add to cart |
| 90 | $0.67 | $69.00 $60.00 (13%) | 🛒 Add to cart |
| 120 | $0.62 | $92.00 $75.00 (18%) | 🛒 Add to cart |
| 180 | $0.58 | $138.00 $105.00 (24%) | 🛒 Add to cart |
| 270 | $0.56 | $207.00 $150.00 (28%) | 🛒 Add to cart |
| 360 |
$0.54
Best per pill
|
$276.00 $193.00 (30%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 180 | $0.36 | $65.00 (0%) | 🛒 Add to cart |
| 270 | $0.35 | $97.50 $94.00 (4%) | 🛒 Add to cart |
| 360 |
$0.34
Best per pill
|
$130.00 $121.00 (7%) | 🛒 Add to cart |
|
Synonyms
|
|||
Furosemide is a high-ceiling loop diuretic indicated for the management of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Its primary mechanism of action involves the inhibition of the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle, resulting in a profound increase in the excretion of water, sodium, chloride, magnesium, and calcium. This potent pharmacologic action makes it a cornerstone therapy in clinical settings where rapid and significant fluid removal is required. Its efficacy and rapid onset of action have established it as a critical agent in both acute and chronic care protocols.
Features
- Pharmacologic Class: Loop diuretic
- Chemical Name: 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid
- Available Formulations: Oral tablets (20 mg, 40 mg, 80 mg), intravenous solution (10 mg/mL), and oral solution
- Bioavailability: Approximately 60-70% for oral administration
- Onset of Action: Oral: 30-60 minutes; IV: within 5 minutes
- Peak Effect: Oral: 1-2 hours; IV: 30 minutes
- Duration of Action: 6-8 hours
- Protein Binding: >98%
- Metabolism: Hepatic (minimal)
- Elimination Half-life: Approximately 0.5-2 hours
- Excretion: Primarily renal (approximately 50% as unchanged drug), with some biliary excretion
Benefits
- Rapid and significant diuresis facilitates prompt reduction in pulmonary and peripheral edema, alleviating symptoms of fluid overload such as dyspnea and peripheral swelling.
- Effective in impaired renal function, as its site of action remains functional even in states of reduced glomerular filtration rate, unlike thiazide diuretics.
- Reduces preload and afterload in congestive heart failure, decreasing cardiac workload and improving hemodynamic parameters.
- Lowers intracranial and intraocular pressure through systemic fluid reduction, providing adjunctive management in specific neurological and ophthalmological conditions.
- Facilitates management of hypercalcemia by promoting calcium excretion, offering a non-pharmacologic approach to acute calcium elevation.
- Versatile administration routes allow for tailored therapy across inpatient, outpatient, and emergency settings.
Common use
Furosemide is predominantly prescribed for the treatment of edema due to various etiologies. Its most frequent application is in managing congestive heart failure, where it reduces extracellular fluid volume, thereby decreasing cardiac preload and mitigating symptoms like orthopnea and paroxysmal nocturnal dyspnea. In hepatic cirrhosis with ascites, it is often used in combination with spironolactone to counteract aldosterone-mediated sodium retention. Within nephrology, it is indicated for edema associated with renal impairment, including acute kidney injury and chronic kidney disease, where it can help manage fluid balance. Off-label uses include the treatment of hypertension (typically when thiazides are insufficient or contraindicated), hypercalcemia, and to aid in the elimination of certain drug overdoses.
Dosage and direction
Dosage must be individualized based on patient response, renal function, and clinical context. For adults, the usual initial oral dose for edema is 20 to 80 mg given as a single dose. Depending on the patient’s response, this dose may be increased by 20 to 40 mg no sooner than 6 to 8 hours after the previous dose. Maintenance doses may be given once or twice daily. For intravenous administration, the initial dose is 20 to 40 mg given as a slow IV push over 1 to 2 minutes. Higher IV doses may be used for patients with refractory edema. In acute pulmonary edema, 40 mg IV is standard, which may be repeated in 1 hour if necessary. For pediatric patients, the oral dose is 2 mg/kg/day as a single dose, which may be increased by 1 to 2 mg/kg no sooner than 6 to 8 hours after the previous dose. The maximum pediatric dose is 6 mg/kg/day. IV dosing in children is 1 mg/kg/dose, which may be increased by 1 mg/kg no sooner than 2 hours after the previous dose. The maximum IV dose is 6 mg/kg. Dosing intervals may need to be extended in patients with severe renal impairment.
Precautions
Close monitoring of fluid and electrolyte balance is imperative during therapy. Serum potassium, sodium, chloride, magnesium, calcium, BUN, and creatinine should be assessed at baseline and periodically during treatment. Patients should be observed for clinical signs of electrolyte imbalance, such as muscle cramps, weakness, dizziness, and cardiac arrhythmias. Blood pressure should be monitored, especially during initial dose titration, to avoid excessive hypotension. In patients with hepatic cirrhosis and ascites, initiation of therapy is best carried out in the hospital due to the risk of precipitating hepatic encephalopathy and electrolyte disturbances. Furosemide may cause glucose intolerance and alter glucose tolerance tests; diabetic patients should be monitored closely. Ototoxicity, which is usually reversible, is associated with rapid intravenous administration, high doses, and concurrent use of other ototoxic drugs. Patients with sulfonamide hypersensitivity may exhibit cross-reactivity.
Contraindications
Furosemide is contraindicated in patients with a known hypersensitivity to furosemide or any component of the formulation. It is also contraindicated in anuria; if anuria does not improve with adequate hydration, treatment should not be continued. It is contraindicated in patients in hepatic coma or states of severe electrolyte depletion until the condition is improved or corrected. Use is contraindicated in patients with a history of hypersensitivity to sulfonamide-derived drugs, as cross-reactivity may occur, though the risk is considered lower with non-antibiotic sulfonamides.
Possible side effect
The most common adverse reactions are related to its pharmacologic effect and include:
- Electrolyte and metabolic disturbances: hypokalemia, hyponatremia, hypochloremia, hypocalcemia, hypomagnesemia, metabolic alkalosis, hyperglycemia, hyperuricemia (may precipitate gout).
- Cardiovascular effects: hypotension, orthostatic hypotension, syncope, thrombophlebitis (with IV administration).
- Ototoxicity: tinnitus, hearing impairment (usually transient with oral administration; may be permanent with rapid IV injection, especially at high doses or with concurrent ototoxic agents).
- Gastrointestinal disturbances: nausea, vomiting, diarrhea, constipation, pancreatitis, cholestatic jaundice.
- Dermatologic reactions: rash, pruritus, photosensitivity, urticaria, necrotizing angiitis (cutaneous vasculitis).
- Hematologic effects: leukopenia, thrombocytopenia, aplastic anemia, agranulocytosis (rare).
- Other: dizziness, headache, blurred vision, paresthesia.
Drug interaction
Furosemide has the potential for numerous significant drug interactions:
- Antihypertensive agents: Potentiates the effects of other antihypertensives, increasing the risk of hypotension.
- Digoxin: Hypokalemia predisposes to digitalis toxicity; close monitoring of potassium levels is essential.
- Lithium: Reduces renal clearance of lithium, increasing the risk of lithium toxicity.
- Nephrotoxic agents (e.g., aminoglycosides, cephalosporins): May increase the risk of ototoxicity and nephrotoxicity.
- NSAIDs: May attenuate the diuretic and antihypertensive effects of furosemide.
- Probenecid: Inhibits the secretion of furosemide, reducing its diuretic efficacy.
- Sucralfate: May reduce the absorption of oral furosemide; administer at least 2 hours apart.
- Corticosteroids, amphotericin B: Concomitant use increases the risk of hypokalemia.
- Cisplatin: Increases the risk of ototoxicity and nephrotoxicity.
- Salicylates: Increased risk of salicylate toxicity at lower doses due to competition for renal secretion.
Missed dose
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to make up for a missed one is not recommended, as it may increase the risk of adverse effects, particularly electrolyte disturbances and hypotension. Patients should be advised not to alter their dosing schedule without consulting their healthcare provider.
Overdose
Overdosage manifests as profound diuresis leading to dehydration, electrolyte depletion (particularly hypokalemia, hyponatremia, hypochloremia), circulatory collapse, and vascular thrombosis and embolism. Symptoms include extreme dizziness, weakness, confusion, syncope, tachycardia, and arrhythmias. Treatment is primarily supportive and symptomatic. Electrolyte levels and fluid status must be monitored and corrected. There is no specific antidote. Hemodialysis does not accelerate elimination significantly due to high protein binding. Management focuses on fluid and electrolyte replacement and hemodynamic support.
Storage
Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), in a tight, light-resistant container. Protect from light and moisture. Keep out of reach of children. Do not freeze the oral solution or intravenous formulation. Discard any unused portion of the oral solution according to the manufacturer’s instructions after the specified period. Do not use if the solution is discolored or contains particulate matter.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. Dosage and indications may vary based on individual patient factors and current medical guidelines. The author and publisher are not responsible for any errors or omissions or for any consequences from application of the information in this document.
Reviews
“Furosemide remains an irreplaceable tool in acute cardiology. Its rapid onset and potent diuresis are crucial for managing decompensated heart failure. The key is vigilant electrolyte monitoring.” — Cardiologist, 15 years experience
“In nephrology, we rely on furosemide for volume management in CKD patients. While effective, the dosing requires careful titration in renal impairment to avoid ototoxicity and further renal injury.” — Nephrologist, 10 years experience
“The IV formulation is a frontline agent in our ICU for fluid overload. The speed of action is impressive, but we always administer it slowly to minimize the risk of ototoxicity.” — Critical Care Specialist, 8 years experience
“As a primary care physician, I use oral furosemide for chronic management of CHF. Patient education on potassium supplementation and symptom monitoring is paramount for safe long-term use.” — General Practitioner, 20 years experience
“In pediatric cardiac care, furosemide is a mainstay. Weight-based dosing and frequent reassessment are critical due to the narrower therapeutic window in children.” — Pediatric Cardiologist, 12 years experience